A phase I/II study of altered fractionated imrt alone for intermediate t-stage oropharyngeal carcinoma

G. Brandon Gunn, Eugene J. Endres, Brent Parker, Maria Pia Sormani, Giuseppe Sanguineti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Purpose: To prospectively assess the feasibility and efficacy of an accelerated and hyperfractionated intensity- modulated radiation therapy (IMRT) schedule for intermediate T-stage oropharyngeal cancer. Patients and Methods: Patients with T3 or unfavorable T2 oropharyngeal squamous cell carcinoma were eligible; a three-dose level simultaneous integrated boost IMRT strategy was used, delivering 78, 69, and 60 Gy to gross disease, high-risk and low-risk target areas, respectively, in 60 twice daily fractions over 6 weeks. No sequential/concomitant systemic treatment or up-front radical surgery was allowed. Median follow-up is 41.7 months (range: 3.5-80.8 months). Results: 25 patients were treated from 11/2002 to 11/2005. 92% of the individual fractions were delivered as scheduled. Grade 3 mucosal and skin toxicity was 100% and 72%, respectively, none of which persisted beyond 12 weeks; a percutaneous endoscopic gastrostomy tube was temporarily placed in 60% of patients. The estimated locoregional progression-free, distant metastases-free, and overall survival rates at 3 years were 86.3% ± 7.4%, 76.4% ± 9.6%, and 70.0% ± 9.6%, respectively. At the same time interval, the actuarial prevalence of grade 3+ CTCAE v3.0 toxicity was 26.1%. Conclusion: While the routine clinical use of this exploratory schedule is discouraged, it may represent the basis for future developments.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalStrahlentherapie und Onkologie
Volume186
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Carcinoma
Appointments and Schedules
Radiotherapy
Oropharyngeal Neoplasms
Gastrostomy
Squamous Cell Carcinoma
Survival Rate
Neoplasm Metastasis
Skin
Therapeutics

Keywords

  • Altered fractionation
  • Intensity-modulated radiation therapy
  • Oropharynx cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

A phase I/II study of altered fractionated imrt alone for intermediate t-stage oropharyngeal carcinoma. / Gunn, G. Brandon; Endres, Eugene J.; Parker, Brent; Sormani, Maria Pia; Sanguineti, Giuseppe.

In: Strahlentherapie und Onkologie, Vol. 186, No. 9, 09.2010, p. 489-495.

Research output: Contribution to journalArticle

Gunn, G. Brandon ; Endres, Eugene J. ; Parker, Brent ; Sormani, Maria Pia ; Sanguineti, Giuseppe. / A phase I/II study of altered fractionated imrt alone for intermediate t-stage oropharyngeal carcinoma. In: Strahlentherapie und Onkologie. 2010 ; Vol. 186, No. 9. pp. 489-495.
@article{3f06dcffaa0e4e56ac5d498a52f13c8b,
title = "A phase I/II study of altered fractionated imrt alone for intermediate t-stage oropharyngeal carcinoma",
abstract = "Background and Purpose: To prospectively assess the feasibility and efficacy of an accelerated and hyperfractionated intensity- modulated radiation therapy (IMRT) schedule for intermediate T-stage oropharyngeal cancer. Patients and Methods: Patients with T3 or unfavorable T2 oropharyngeal squamous cell carcinoma were eligible; a three-dose level simultaneous integrated boost IMRT strategy was used, delivering 78, 69, and 60 Gy to gross disease, high-risk and low-risk target areas, respectively, in 60 twice daily fractions over 6 weeks. No sequential/concomitant systemic treatment or up-front radical surgery was allowed. Median follow-up is 41.7 months (range: 3.5-80.8 months). Results: 25 patients were treated from 11/2002 to 11/2005. 92{\%} of the individual fractions were delivered as scheduled. Grade 3 mucosal and skin toxicity was 100{\%} and 72{\%}, respectively, none of which persisted beyond 12 weeks; a percutaneous endoscopic gastrostomy tube was temporarily placed in 60{\%} of patients. The estimated locoregional progression-free, distant metastases-free, and overall survival rates at 3 years were 86.3{\%} ± 7.4{\%}, 76.4{\%} ± 9.6{\%}, and 70.0{\%} ± 9.6{\%}, respectively. At the same time interval, the actuarial prevalence of grade 3+ CTCAE v3.0 toxicity was 26.1{\%}. Conclusion: While the routine clinical use of this exploratory schedule is discouraged, it may represent the basis for future developments.",
keywords = "Altered fractionation, Intensity-modulated radiation therapy, Oropharynx cancer",
author = "Gunn, {G. Brandon} and Endres, {Eugene J.} and Brent Parker and Sormani, {Maria Pia} and Giuseppe Sanguineti",
year = "2010",
month = "9",
doi = "10.1007/s00066-010-2093-6",
language = "English",
volume = "186",
pages = "489--495",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "9",

}

TY - JOUR

T1 - A phase I/II study of altered fractionated imrt alone for intermediate t-stage oropharyngeal carcinoma

AU - Gunn, G. Brandon

AU - Endres, Eugene J.

AU - Parker, Brent

AU - Sormani, Maria Pia

AU - Sanguineti, Giuseppe

PY - 2010/9

Y1 - 2010/9

N2 - Background and Purpose: To prospectively assess the feasibility and efficacy of an accelerated and hyperfractionated intensity- modulated radiation therapy (IMRT) schedule for intermediate T-stage oropharyngeal cancer. Patients and Methods: Patients with T3 or unfavorable T2 oropharyngeal squamous cell carcinoma were eligible; a three-dose level simultaneous integrated boost IMRT strategy was used, delivering 78, 69, and 60 Gy to gross disease, high-risk and low-risk target areas, respectively, in 60 twice daily fractions over 6 weeks. No sequential/concomitant systemic treatment or up-front radical surgery was allowed. Median follow-up is 41.7 months (range: 3.5-80.8 months). Results: 25 patients were treated from 11/2002 to 11/2005. 92% of the individual fractions were delivered as scheduled. Grade 3 mucosal and skin toxicity was 100% and 72%, respectively, none of which persisted beyond 12 weeks; a percutaneous endoscopic gastrostomy tube was temporarily placed in 60% of patients. The estimated locoregional progression-free, distant metastases-free, and overall survival rates at 3 years were 86.3% ± 7.4%, 76.4% ± 9.6%, and 70.0% ± 9.6%, respectively. At the same time interval, the actuarial prevalence of grade 3+ CTCAE v3.0 toxicity was 26.1%. Conclusion: While the routine clinical use of this exploratory schedule is discouraged, it may represent the basis for future developments.

AB - Background and Purpose: To prospectively assess the feasibility and efficacy of an accelerated and hyperfractionated intensity- modulated radiation therapy (IMRT) schedule for intermediate T-stage oropharyngeal cancer. Patients and Methods: Patients with T3 or unfavorable T2 oropharyngeal squamous cell carcinoma were eligible; a three-dose level simultaneous integrated boost IMRT strategy was used, delivering 78, 69, and 60 Gy to gross disease, high-risk and low-risk target areas, respectively, in 60 twice daily fractions over 6 weeks. No sequential/concomitant systemic treatment or up-front radical surgery was allowed. Median follow-up is 41.7 months (range: 3.5-80.8 months). Results: 25 patients were treated from 11/2002 to 11/2005. 92% of the individual fractions were delivered as scheduled. Grade 3 mucosal and skin toxicity was 100% and 72%, respectively, none of which persisted beyond 12 weeks; a percutaneous endoscopic gastrostomy tube was temporarily placed in 60% of patients. The estimated locoregional progression-free, distant metastases-free, and overall survival rates at 3 years were 86.3% ± 7.4%, 76.4% ± 9.6%, and 70.0% ± 9.6%, respectively. At the same time interval, the actuarial prevalence of grade 3+ CTCAE v3.0 toxicity was 26.1%. Conclusion: While the routine clinical use of this exploratory schedule is discouraged, it may represent the basis for future developments.

KW - Altered fractionation

KW - Intensity-modulated radiation therapy

KW - Oropharynx cancer

UR - http://www.scopus.com/inward/record.url?scp=77957758819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957758819&partnerID=8YFLogxK

U2 - 10.1007/s00066-010-2093-6

DO - 10.1007/s00066-010-2093-6

M3 - Article

C2 - 20803186

AN - SCOPUS:77957758819

VL - 186

SP - 489

EP - 495

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 9

ER -